Who are RVT-101's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): TAU, TAU-284, TRx0237, Tau PET scan using MK-6240, Experimental: ALZ-801.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rvt-101.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

RVT-101 — Competitive Intelligence Brief

RVT-101 (RVT-101) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: tau protein inhibitor. Area: Neurology.

phase 3 tau protein inhibitor tau protein Neurology Small molecule Live · refreshed every 30 min

Target snapshot

RVT-101 (RVT-101) — Axovant Sciences Ltd.. RVT-101 is a small molecule that targets the tau protein to treat neurodegenerative diseases.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
RVT-101 TARGET	RVT-101	Axovant Sciences Ltd.	phase 3	tau protein inhibitor	tau protein
TAU	TAU	Montefiore Medical Center	marketed	Tau protein aggregation inhibitor	Tau protein
TAU-284	TAU-284	Tanabe Pharma Corporation	phase 3	Tau aggregation inhibitor	Tau protein
TRx0237	TRx0237	TauRx Therapeutics Ltd	phase 3	tau aggregation inhibitor	tau protein
Tau PET scan using MK-6240	Tau PET scan using MK-6240	University of California, Irvine	phase 3	PET imaging agent	Tau protein (paired helical filaments)
Experimental: ALZ-801	Experimental: ALZ-801	Alzheon Inc.	phase 3	Tau aggregation inhibitor	Tau protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (tau protein inhibitor class)

Axovant Sciences Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). RVT-101 — Competitive Intelligence Brief. https://druglandscape.com/ci/rvt-101. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab